Stock Events

Stock Events

Vaxart 

€0.6000
0
+€0.00+0% Monday 13:20

Statistics

Day High
0.6
Day Low
0.42
52W High
0.79
52W Low
0.2212
Volume
400
Avg. Volume
6,851
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q1 2026
Next
-0.03
-0.01
0
0.02
Expected EPS
-0.0263067
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NB11.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.6B
Novavax is a direct competitor in the development of vaccines, including those for COVID-19, similar to Vaxart's oral vaccine efforts.
Moderna
MRNA
Mkt Cap31.65B
Moderna is a leader in mRNA vaccine technology, competing in the same space as Vaxart's novel vaccine platform.
Pfizer
PFE
Mkt Cap138.61B
Pfizer, with its COVID-19 vaccine developed in collaboration with BioNTech, competes in the vaccine market, including areas Vaxart is targeting.
BioNTech
BNTX
Mkt Cap24.67B
BioNTech partners with Pfizer on COVID-19 vaccines, directly competing with Vaxart's vaccine development efforts.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson developed a COVID-19 vaccine, competing in the broader vaccine market where Vaxart is also a player.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca competes in the COVID-19 vaccine space, an area where Vaxart is also trying to make an impact with its oral vaccine candidates.
Inovio Pharmaceuticals
INO
Mkt Cap100.37M
Inovio Pharmaceuticals is focused on DNA medicines, including vaccines, making it a competitor in the innovative vaccine technology space like Vaxart.
Sanofi
SNY
Mkt Cap103.32B
Sanofi is a large pharmaceutical company with a broad vaccine portfolio, competing in the same market as Vaxart.
GSK
GSK
Mkt Cap107.47B
GlaxoSmithKline has a significant presence in the vaccine market, making it a competitor to Vaxart in the quest to develop and commercialize vaccines.

About

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Show more...
CEO
Mr. Cezar Andrei Floroiu M.B.A.
Employees
110
Country
United States
ISIN
US92243A2006

Listings

STU
DE
NB11.STU
MX
MX
VXRT.MX
MU
DE
NB11.MU
OTC Link
US
VXRT

0 Comments

Share your thoughts

FAQ

What is Vaxart stock price today?▼
The current price of NB11.STU is €0.60 EUR — it has increased by +0% in the past 24 hours. Watch Vaxart stock price performance more closely on the chart.
What is Vaxart stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Vaxart stocks are traded under the ticker NB11.STU.
When is the next Vaxart earnings date?▼
Vaxart is going to release the next earnings report on July 30, 2026.
What were Vaxart earnings last quarter?▼
NB11.STU earnings for the last quarter are 0.02 EUR per share, whereas the estimation was 0.02 EUR resulting in a +0% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Vaxart have?▼
As of July 08, 2026, the company has 110 employees.
In which sector is Vaxart located?▼
Vaxart operates in the Health & Wellness sector.
When did Vaxart complete a stock split?▼
Vaxart has not had any recent stock splits.
Where is Vaxart headquartered?▼
Vaxart is headquartered in South San Francisco, United States.